Characteristic | All patients n = 288 (%) | Patients treated only with mAbs n = 94 | Patients treated only with antivirals n = 171 | Patients treated with both mAbs and antivirals n = 23 |
---|---|---|---|---|
Gender n (%) | ||||
Male | 151 (52.4%) | 50 (53.2%) | 87 (50.9%) | 14 (60.9%) |
Female | 137 (47.6%) | 44 (46.8%) | 84 (49.1%) | 9 (39.1%) |
Age | ||||
Mean (SD) | 63.6 (± 16.1) | 67 (± 15.1) | 62.4 (± 16.5) | 58.3 (± 15.8) |
65 years or older n (%) | 158 (54.9%) | 59 (62.8%) | 91 (53.2%) | 8 (34.8%) |
Mean BMI (SD) | 28.3 (± 6.1) | 29.2 (± 6.6) | 27.8 (± 5.7) | 27.8 (± 5.8) |
Comorbidities n (%) | ||||
Cardiac insufficiency | 14 (4.9%) | 4 (4.3%) | 8 (4.7%) | 2 (8.7%) |
Cerebral ischemia history | 28 (10.9%) | 13 (13.8%) | 13 (7.6%) | 2 (8.7%) |
COPD | 53 (18.4%) | 13 (13.8%) | 37 (21.6%) | 3 (13%) |
Autoimmune diseases | 36 (12.5%) | 7 (7.4%) | 25 (14.6%) | 4 (17.4%) |
Vasculopathy | 24 (8.3%) | 12 (12.8%) | 9 (5.3%) | 3 (13%) |
Hepatic cirrhosis | 6 (2.1%) | 1 (1.1%) | 5 (2.9%) | 0 |
Obesity | 91 (31.6%) | 35 (37.2%) | 51 (29.8%) | 5 (21.7%) |
Diabetes | ||||
Compensated disease | 63 (21.9%) | 24 (25.5%) | 36 (21.1%) | 3 (13%) |
Decompensated disease | 10 (3.5%) | 3 (3.2%) | 6 (3.5%) | 1 (4.3%) |
Chronic kidney diseases | 19 (6.6%) | 9 (9.6%) | 7 (4.1%) | 3 (13%) |
Solid cancer | ||||
Localized disease | 34 (11.8%) | 6 (6.4%) | 23 (13.5%) | 5 (21.7%) |
Metastatic disease | 15 (5.2%) | 3 (3.2%) | 12 (7.1%) | 0 |
Hematological malignancies | 43 (14.9%) | 10 (10.6%) | 23 (13.5%) | 10 (43.5%) |
AIDS | 1 (0.3%) | 1 (1.1%) | 0 | 0 |
History of peptic ulcer | 2 (0.7%) | 0 | 2 (1.2%) | 0 |
Ischemic heart diseases | 36 (12.5%) | 15 (16%) | 17 (9.9%) | 4 (17.4%) |
Dementia | 17 (5.9%) | 10 (10.6%) | 7 (4.1%) | 0 |
Hemiplegia | 3 (1%) | 1 (1.1%) | 1 (0.6%) | 1 (4.3%) |
Hypertension | 165 (57.3%) | 60 (63.8%) | 93 (54.4%) | 12 (52.2%) |
Number of comorbidities ≥ 3 | 113 (39.2%) | 44 (46.8%) | 60 (35.1%) | 9 (39.1%) |
Charlson Comorbidity Index (mean ± SD) | 4.1 (± 2.3) | 4.2 (± 2.2) | 4 (± 2.3) | 4.1 (± 2.2) |
Vaccination | ||||
Yes | 232 (82.3%) | 56 (59.6%) | 161 (94.2%) | 18 (78.3%) |
No | 51 (17.7%) | 38 (40.4%) | 10 (5.8%) | 5 (21.7%) |
Mean days from symptoms onset to first positive swab (SD) | 1.3 (1.4) | 1.7 (1.7) | 1.2 (1.2) | 1.1 (1.1) |
Mean days from symptoms onset to treatment (SD) | 3.3 (1.9) | 3.9 (2.4) | 3.1 (1.5) | 3.5 (2.2) |
Baseline clinical severity n (%) | ||||
ASY | 47 (16.3%) | 39 (41.5%) | 3 (1.8%) | 5 (21.7%) |
MID | 235 (81.6%) | 52 (55.3%) | 167 (97.6%) | 16 (69.6%) |
MOD | 6 (2.1%) | 3 (3.2%) | 1 (0.6%) | 2 (8.7%) |
IgG anti-SARS-CoV-2-Spike protein at baseline n (%) | ||||
Positive | 70 (24.3%) | 45 (47.9%) | 18 (10.5%) | 7 (30.4%) |
Negative | 65 (22.6%) | 46 (48.9%) | 4 (2.3%) | 15 (65.2%) |
N/A | 153 (53.1%) | 3 (3.2%) | 149 (87.1%) | 1 (4.3%) |
Monoclonal antibodies n (%)* | ||||
Bamlanivimab/Etesevimab | 42 (35.9%) | 40 (42.6%) | – | 2 (8.7%) |
Casirivimab/Imdevimab | 22 (18.8%) | 17 (18.1%) | – | 5 (21.7%) |
Sotrovimab | 53 (45.3%) | 37 (39.4%) | – | 16 (69.6%) |
**Total number | 117 | 94 | – | 23 |
Antivirals n (%)* | ||||
Remdesivir | 57 (29.1%) | – | 38 (22.2%) | 18 (78.3%) |
Molnupiravir | 77 (39.8%) | – | 75 (43.9%) | 2 (8.7%) |
Nirmatrelvir/Ritonavir | 61 (31.1%) | – | 58 (33.9%) | 3 (13%) |
**Total number | 195 | – | 171 | 23 |
COVID-19 progression and related hospital admission | ||||
Yes | 4 (1.4%) | 3 (3.2%) | 1 (0.6%) | 0 |
No | 284 (98.6%) | 91 (96.8%) | 170 (99.4%) | 23 (100%) |